5 suspended. 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Suspended 5 |
| Phase 3 | 1 | Suspended 1 |
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Dose Finding Study of DAOIB Added to tDCS for AD DAOIB - Transcranial Direct Current Stimulation, Dementia | Phase 2 | Suspended | Chang Gung Memorial Hospital | 140 | 2027-01-01 | 2026-03-20 |
| Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV Pramipexole ER, Escitalopram - Major Depressive Disorder, Mild Neurocognitive Disorder | Phase 2 | Suspended | National Institute of Allergy and Infectious Diseases (NIAID) | 186 | 2026-05-17 | 2026-07-14 |
| An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome Psilocybin, 1.5 mg - Fragile X Syndrome, Behavior | Phase 2 | Suspended | Nova Mentis Life Science Corp | 10 | 2023-03-28 | 2024-05-08 |
| Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients Angiotensin-(1-7), Memory Training - Chronic Heart Failure, Cognitive Impairment | Phase 2 | Suspended | University of Arizona | 6 | 2016-04-01 | 2025-06-04 |
| Target Hemodynamics and Brain Injury During General Anesthesia in the Elderly Hemodynamic target, Phenylephrine, Intravenous fluids - Post-operative Cognitive Dysfunction | Phase 2 / Phase 3 | Suspended | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 1812 | 2014-10-01 | 2018-04-13 |
Cognitive Dysfunction (3) · Behavior (1) · Delirium (1) · Dementia (1) · Depressive Disorder, Major (1) · Fragile X Syndrome (1) · Neurobehavioral Manifestations (1)
Mental Disorders (5) · Cognition Disorders (3) · Nervous System Diseases (3) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Chromosome Disorders (1) · Confusion (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Depressive Disorder (1) · Genetic Diseases, Inborn (1)
Cognitive Training (1) · Dopamine (1) · Ephedrine (1) · Epinephrine (1) · Escitalopram (1) · Norepinephrine (1) · Phenylephrine (1) · Psilocybin (1) · angiotensin I (1-7) (1)
Chang Gung Memorial Hospital (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Nova Mentis Life Science Corp (1) · University of Arizona (1)
United States (2) · Botswana (1) · Brazil (1) · Canada (1) · India (1) · Italy (1) · Kenya (1) · Malawi (1) · Mexico (1) · Peru (1) · Philippines (1) · South Africa (1) · Taiwan (1) · Thailand (1) · Uganda (1)
Alessandro Santini, MD (1) · Antonio Pesenti, MD (1) · David Crowley, MD (1) · Luciano Gattinoni, MD, FRCP (1) · Marvin Hausman, MD (1) · Michael Quintel, MD, PhD (1) · Nancy K Sweitzer, MD, PhD (1) · Scott Letendre, MD (1) · Thomas Langer, MD (1) · William R Short, MD (1)